UnknownPhase 2

Low Dose Atropine for Symptomatic Vitreous Floaters

United States200 participantsStarted 2024-01-01

Plain-language summary

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants. Exclusion Criteria: * Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

What they're measuring

Symptom improvement assessed by questionnaire

Timeframe: Up to 2 months

Trial details

NCT IDNCT06174935

SponsorJeanette Du

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-01

Contact for this trial

Jeanette Du, MD

844-749-3627 JDu@rgw.com

View on ClinicalTrials.gov More Vitreous Floaters trials